

**In the specification**

Please amend the paragraph starting at page 7, line 6, as follows:

The preferred formulations of liposomes comprise dipalmitoylphosphatidylcholine (DPPC):dipalmitoylphosphatidylglycerol (DPPG) in a molar ratio of 10: 3 (thereafter illustrative of conventional liposomes). In another embodiment, formulations of liposomes comprise diacylphosphatidylcholine: diacylphosphatidylglycerol in a molar ratio of about 10:3. In another embodiment, formulations of liposomes comprise a mixture of diacylphosphatidylcholine: diacylphosphatidylglycerol: diacylphosphatidylethanol-amine-polyethyleneglycol in a molar ratio of 10:3:0.1-3. In another embodiment, formulations of liposomes comprise a mixture of dipalmitoylphosphatidylcholine:dipalmitoylphosphatidylglycerol in a molar ratio of 10:3 or distearoylphosphatidylcholine:distearoylphosphatidylglycerol in a molar ratio of 10:3. In another preferred embodiment, formulations of liposomes comprise DPPC:DPPG:distearoylphosphatidylethanolamine-polyethyleneglycol (DSPE-PEG) in a molar ratio of 10: 3: 0.83 (thereafter illustrative of sterically stabilized liposomes or stealth liposomes). In another embodiment, formulations of liposomes comprise a mixture of dipalmitoylphosphatidylcholine:dipalmitoylphosphatidylglycerol: dipalmitoylphosphatidylethanolamine-polyethyleneglycol in a molar ratio of 10:3:0.33 or dipalmitoylphosphatidylcholine: dipalmitoylphosphatidylglycerol: distearoylphosphatidylethanolamine-polyethyleneglycol in a molar ratio of 10:3:0.83. In still another preferred embodiment, formulations of liposomes comprise DPPC: DPPG:dipalmitoylphosphatidylethanolamine-N-(4- (p-maleimidophenyl) butyryl) (DPPE-MPB) in a molar ratio of 10: 3: 0.33 bearing anti-HLA-DR Fab' fragments (thereafter illustrative of anti-HLA-DR immunoliposomes). In still another preferred embodiment, formulations of liposomes comprise DPPC:DPPG:DPPE-MPB in a molar ratio of 10: 3: 0.33 bearing anti-CD4 Fab' fragments (thereafter illustrative of anti-CD4 immunoliposomes). In still another preferred embodiment, formulations of liposomes comprise DPPC:DPPG:DSPE-polyethyleneglycol-MPB (DSPE-PEG-MPB) in a molar ratio of 10: 3: 0.83 bearing anti-HLA-DR Fab' fragments (thereafter illustrative of sterically stabilized anti-HLA-DR immunoliposomes or stealth anti-HLA-DR immunoliposomes). In still another preferred embodiment, formulations of

liposomes comprise DPPC:DPPG:DSPE-PEG-MPB in a molar ratio of 10: 3: 0.83 bearing anti-CD4 Fab' fragments (thereafter illustrative of sterically stabilized anti-CD4 immunoliposomes or stealth anti-CD4 immunoliposomes). MPB is a coupling agent that may be ~~replace~~ replaced with any other suitable molecule for the purpose of attaching a ligand to a lipid or lipid derivative.